
    
      This is a multicenter, open-label, randomized, Phase II study of preoperative MM-121 with
      paclitaxel in HER2-negative breast cancer. Patients will be randomized to receive paclitaxel
      with or without MM-121 for 12 weeks followed by 4 cycles of doxorubicin plus cyclophosphamide
      and subsequent surgery.
    
  